FY2025 · ended Dec 31, 2025 · Revenue $5.07M, -2.8% YoY · Filed Mar 30, 2026
Ensysce Biosciences, Inc. (ENSC) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $5.1 million and a net loss of $10.2 million. Free cash flow was -$7.9 million.
Revenue (TTM)
$4.50M
-39.3% vs year-ago TTM
Net income (TTM)
$-12.62M
-91.8% vs year-ago TTM
Operating cash flow (TTM)
$-8.86M
-42.9% vs year-ago TTM
Free cash flow
$-7.93M
EPS (TTM)
$-1.92
+61.0% vs year-ago TTM
Dividend per share
None
Shares outstanding
9.28M
+560.3% vs prior year
Net cash
$3.12M
FY 2022
Operating margin
-281.3%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ENSC (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- La Jolla, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1716947
- Former names
- Leisure Acquisition Corp. (until Jun 30, 2021)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $5.1M | $5.2M | $2.2M | $2.5M | $3.5M |
| Operating income | -$10.2M | -$6.7M | -$10.7M | -$24.2M | -$19.9M |
| Net income | -$10.2M | -$8.0M | -$10.6M | -$24.2M | -$29.1M |
| Diluted EPS | -$3.98 | -$11.45 | -$70.40 | — | -$1.48 |
| Operating cash flow | -$7.8M | -$7.5M | -$10.8M | -$17.9M | -$8.2M |
| Free cash flow | -$7.9M | — | — | — | — |
| Total assets | $7.5M | $5.6M | $2.7M | $5.9M | $16.4M |
| Total liabilities | $4.6M | $2.2M | $3.4M | $9.9M | $24.6M |
| Stockholders' equity | $3.2M | $3.7M | -$322,858 | -$3.7M | -$7.9M |
| Cash and investments | $4.3M | $3.5M | $1.1M | $3.1M | $12.3M |
| Total debt | — | — | — | $27,315 | $24,874 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Officer or director change
|
Nov 4, 2026 | Oct 29, 2026 |
| 8-K/A | Amended current report | Oct 16, 2026 | Aug 5, 2026 |
| 8-K |
Current report
Bylaw or fiscal year change
|
Sep 29, 2026 | Sep 25, 2026 |
| 8-K |
Current report
Other events
|
Aug 25, 2026 | Aug 25, 2026 |
| 8-K |
Current report
Other events
|
Aug 24, 2026 | Aug 24, 2026 |
| 10-Q | Quarterly report | Aug 13, 2026 | Jun 30, 2026 |
All 547 Ensysce Biosciences, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.